Neurohormonal changes after implantation of a left ventricular assist system

ASAIO Journal

Volumn 44, Issue 4, 1998, Pages 299-302

  Delcado, Reynolds ^a,b   Radovancevic, Branislav ^a   Massin, Edward K ^a   Frazier, O H ^a,b   Benedict, Claude ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b TEXAS HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR SYSTEM; HEMODYNAMICS; HORMONES; NEUROPHYSIOLOGY; TRANSPLANTATION (SURGICAL);

LEFT VENTRICULAR ASSIST SYSTEM (LVAS); NEUROHORMONAL LEVELS;

HEART VALVE PROSTHESES;

NORADRENALIN;

ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; HEART DISEASE; HEART TRANSPLANTATION; HEART VENTRICLE CONTRACTION; HUMAN; IMPLANT; IMPLANTATION; LONG TERM CARE; NORADRENALIN BLOOD LEVEL; PROGNOSIS; QUALITY OF LIFE;

EID: 0345310053     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-199807000-00011     Document Type: Article

References (15)

1. FrazierOH: First use of an untethered, vented electric left ventricular assist device for long-term support. Circulation 89: 2908-2914, 1994.
2. Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkhoff D: Reversal of chronic ventricular dilatation in patients with endstage cardiomyopathy by prolonged mechanical unloading. Circulation 91: 2717-2720, 1995.
3. McCarthy PM, Savage RM, Fraser CD, et al: Hemodynamic and physiologic changes during support with an implantable left ventricular assist device. J Thorac Cardiovasc Surg 109: 409417, 1995.
4. Frazier OH, Macris MP, Myers TJ, et al: Improved survival after extended bridge to cardiac transplantation. Ann Thorac Surg 57: 1416-1422, 1994.
5. McCarthy PM, Nakatani S, Vargo R, etal: Structural and left ventricular histologie changes after implantable LVAD insertion. Ann Thorac Surg 59: 609-613, 1995.
6. Frazier OH, Benedict CR, Radovancevic B, et al: Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg 62: 675-681, 1996.
7. Benedict CR: Neurohormonal aspects of heart failure. Cardiol Clin 12:9-23, 1994.
8. Swedberg K, Eneroth P, Kjekshus J, et al: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 87: 17301736, 1990.
9. Francis GS, Benedict C, Johnstone DE, étal., for the SOLVD Investigators: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82: 1724-1229, 1990.
10. James KB, McCarthy PM, Thomas JD, et al: Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation 92(Suppl II): II-191-II-195, 1995.
11. Hussain MN, Benedict CR: Radioenzymatic microassay for simultaneous estimations of dopamine, norepinephrine and epineph-rine in plasma, urine and tissues. Clin Criem31: 1861-1864 1985.
12. Frazier OH, Rose EA, Macmanus Q, et al: Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. Ann Thorac Surg 53: 1080-1090, 1992.
13. Thomas JA, Marks BH: Plasma norepinephrine in congestive heart failure. Am J Cardiol 41: 233-243, 1978.
14. Lonn EM, Yusuf S, Jha P, et al: Emerging role of angiotensinconverting enzyme inhibitors in cardiac and vascular protection. Circulation 90: 2056-2069, 1994.
15. Estrada-Quintero T, Uretsky BF, Murali S, Griffith BP, Kormos RL: Neurohormonal activation and exercise function in patients with severe heart failure and patients with left ventricular assist system. Chest 107: 1499-1503, 1995.